These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37869789)

  • 1. Previous exposure to Spike-providing parental strains confers neutralizing immunity to XBB lineage and other SARS-CoV-2 recombinants in the context of vaccination.
    Suryawanshi RK; Taha TY; McCavitt-Malvido M; Silva I; Khalid MM; Syed AM; Chen IP; Saldhi P; Sreekumar B; Montano M; Foresythe K; Tabata T; Kumar GR; Sotomayor-Gonzalez A; Servellita V; Gliwa A; Nguyen J; Kojima N; Arellanor T; Bussanich A; Hess V; Shacreaw M; Lopez L; Brobeck M; Turner F; Wang Y; Ghazarian S; Davis G; Rodriguez D; Doudna J; Spraggon L; Chiu CY; Ott M
    Emerg Microbes Infect; 2023 Dec; 12(2):2270071. PubMed ID: 37869789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1.
    Hu Y; Zou J; Kurhade C; Deng X; Chang HC; Kim DK; Shi PY; Ren P; Xie X
    Emerg Microbes Infect; 2023 Dec; 12(2):2271089. PubMed ID: 37824708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
    Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
    Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination
    Wang H; Xue Q; Zhang H; Yuan G; Wang X; Sheng K; Li C; Cai J; Sun Y; Zhao J; Lu J; Fang S; Yang Y; Zhang Y; Huang Y; Wang J; Xu JH; Jiang MX; Wang X; Shen L; Liu Y; Liu Q; Zhang Q; Wang S; Wang P; Qiu C; Ai J; Zhang W
    Emerg Microbes Infect; 2023 Dec; 12(2):2249121. PubMed ID: 37668156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants.
    Li H; Yang C; Yin L; Liu W; Zhang Z; Liu B; Sun X; Liu W; Lin Z; Liu Z; He P; Feng Y; Wang C; Wang W; Guan S; Wang Q; Chen L; Li P
    Emerg Microbes Infect; 2024 Dec; 13(1):2387447. PubMed ID: 39082740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
    Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
    mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
    Cheng SMS; Mok CKP; Li JKC; Chan KKP; Luk KS; Lee BHW; Gu H; Chan KCK; Tsang LCH; Yiu KYS; Ling KKC; Tang YS; Luk LLH; Yu JKM; Pekosz A; Webby RJ; Cowling BJ; Hui DSC; Peiris M
    Virol J; 2024 Mar; 21(1):70. PubMed ID: 38515117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
    da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection.
    Springer DN; Camp JV; Aberle SW; Deutsch J; Lammel O; Weseslindtner L; Stiasny K; Aberle JH
    J Med Virol; 2024 Jul; 96(7):e29801. PubMed ID: 38988204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection.
    Zhu KL; Jiang XL; Zhan BD; Wang XJ; Xia X; Cao GP; Sun WK; Huang PX; Zhang JZ; Gao YL; Dai EH; Gao HX; Ma MJ
    Cell Rep; 2023 Feb; 42(2):112075. PubMed ID: 36774551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
    Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
    Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Neutralizing Activity against Omicron Subvariants in BA.5 Breakthrough Infection and Three-Dose Vaccination Using a Novel Chemiluminescence-Based, Virus-Mediated Cytopathic Assay.
    Toyoda M; Tan TS; Motozono C; Barabona G; Yonekawa A; Shimono N; Minami R; Nagasaki Y; Miyashita Y; Oshiumi H; Nakamura K; Matsushita S; Kuwata T; Ueno T
    Microbiol Spectr; 2023 Aug; 11(4):e0066023. PubMed ID: 37310218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster.
    Wang X; Jiang S; Ma W; Li X; Wei K; Xie F; Zhao C; Zhao X; Wang S; Li C; Qiao R; Cui Y; Chen Y; Li J; Cai G; Liu C; Yu J; Li J; Hu Z; Zhang W; Jiang S; Li M; Zhang Y; Wang P
    Cell Host Microbe; 2024 Jan; 32(1):25-34.e5. PubMed ID: 38029742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
    Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
    Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy.
    Trombetta CM; Marchi S; Leonardi M; Coppola C; Benincasa L; Marotta MG; Buonvino N; Maes P; Stufano A; Pontrelli D; Vasinioti VI; Manenti A; Camero M; Montomoli E; Decaro N; Lovreglio P
    Acta Trop; 2023 Dec; 248():107042. PubMed ID: 37863379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 BA.1 and BA.2 breakthrough infections boost antibody responses to early Omicron subvariants but not BQ.1.1 or XBB.1.5.
    Abbad A; Yellin T; Singh G; Fried M; Raskin A; Tcheou J; Monahan B; Gleason C; ; Simon V; Carreño JM; Krammer F
    Cell Rep Med; 2024 Mar; 5(3):101474. PubMed ID: 38508136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.
    Kim E; Khan MS; Ferrari A; Huang S; Sammartino JC; Percivalle E; Kenniston TW; Cassaniti I; Baldanti F; Gambotto A
    Microbiol Spectr; 2023 Jun; 11(3):e0436322. PubMed ID: 37162333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated Omicron infection dampens immune imprinting from previous vaccination and induces broad neutralizing antibodies against Omicron sub-variants.
    Gong X; Peng L; Wang F; Liu J; Tang Y; Peng Y; Niu S; Yin J; Guo L; Lu H; Liu Y; Yang Y
    J Infect; 2024 Aug; 89(2):106208. PubMed ID: 38908522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.